Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 6,433 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Oxalate Absorption in Calcium Oxalate Stone Disease

NCT06331546
View directory record Official record
Conditions
Kidney Stone, Kidney Calculi, Urolithiasis, Urolithiasis, Calcium Oxalate, Nephrolithiasis, Nephrolithiasis, Calcium Oxalate, Oxalate Urolithiasis, Oxaluria, Healthy
Interventions
Low-oxalate diet, High-oxalate diet, soluble oxalate gut absorption test
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 5:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

NCT00670774
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 22, 2026, 5:46 AM EDT
Completed No phase listed Observational

Carnitine, Aclycarnitine, Myocardial Function, and CRRT

NCT01941823
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Not listed
Lead sponsor
Asha Moudgil
Other
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Not applicable Interventional

Pathophysiology of Uric Acid Nephrolithiasis

NCT00904046
View directory record Official record
Conditions
Uric Acid Kidney Stone Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 22, 2026, 5:46 AM EDT
Terminated Not applicable Interventional Results available

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pioglitazone, Placebo, Nitroglycerin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

Quanta Home Run Trial

NCT04975880
View directory record Official record
Conditions
Renal Failure
Interventions
SC+ Hemodialysis System
Device
Lead sponsor
Quanta Dialysis Technologies Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Sacramento, California • San Diego, California • San Leandro, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

NCT02460146
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
CXA-10, CXA-10 placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

NCT01340586
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

NCT00588666
View directory record Official record
Conditions
Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
Interventions
Bevacizumab, Carboplatin, Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 22, 2026, 5:46 AM EDT
Active, not recruiting Not applicable Interventional

Potassium Citrate and Crystal Light Lemonade

NCT05389995
View directory record Official record
Conditions
Kidney Stone
Interventions
Potassium citrate, Crystal light, Potassium citrate + crystal light
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration

NCT01064739
View directory record Official record
Conditions
Healthy Participants
Interventions
Fava beans, Fixed Sodium Diet
Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 22, 2026, 5:46 AM EDT
Not listed Not applicable Interventional

Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis

NCT01892839
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
low dialysate flow, smaller dialyzer, high dialysate flow, larger dialyzer
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Not applicable Interventional

Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study

NCT07487701
View directory record Official record
Conditions
Migraine
Interventions
Nerivio REN device
Device
Lead sponsor
Theranica
Industry
Eligibility
8 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure

NCT00280072
View directory record Official record
Conditions
Kidney Failure, Acute
Interventions
Renal Assist Device
Device
Lead sponsor
RenaMed Biologics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis

NCT00943995
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Dialysis
Interventions
somatropin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

NCT00770081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
vildagliptin, sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 1 Interventional

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

NCT01048892
View directory record Official record
Conditions
Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
Seneca Valley virus-001, cyclophosphamide, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 22, 2026, 5:46 AM EDT
Terminated Phase 1 Interventional

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

NCT04301011
View directory record Official record
Conditions
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
Interventions
TBio-6517, Pembrolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

NCT04750577
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Placebo matching BI 685509, BI 685509
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Victorville, California • Waterbury, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 22, 2026, 5:46 AM EDT
Recruiting Phase 4 Interventional

Infliximab for Immune Checkpoint Inhibitor Associated AKI

NCT07683975
View directory record Official record
Conditions
Acute Kidney Injury, Acute Interstitial Nephritis
Interventions
Infliximab, Prednisone, prednisone (oral)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 5:46 AM EDT
Completed No phase listed Observational

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

NCT01686607
View directory record Official record
Conditions
Systemic Fungal Infections
Interventions
Parenteral micafungin application, Other parenteral antifungal drugs
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
Not listed
Enrollment
40,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 22, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

NCT01324245
View directory record Official record
Conditions
Salt-sensitive Hypertension
Interventions
Fenoldopam
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 22, 2026, 5:46 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology

NCT06753045
View directory record Official record
Conditions
Heart Diseases
Interventions
Smartwatch
Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 5:46 AM EDT